Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/24/2026, 12:00:00 AM
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
Korean Translation
미국 FDA의 피하주사형 레켐비(LEQEMBI IQLIK) 치료 시작에 대한 결정이 예정됨. FDA는 이 보충 생물학적 제제 허가 신청(sBLA)에 대해 우선 심사를 부여했으며, 전문의약품 허가 신청자 비용 부담법(PDUFA)에 따른 목표일은 2026년 5월 24일로 예상됨. 새로운 투여 방식의 상당한 시장 잠재력으로 인해 높은 주가 영향이 예상됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Q1 2026 earnings release is scheduled. Impact is estimated to be low as it is a routine quarterly announcement.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release is scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva announced it will release its financial results for the first quarter of 2026 on April 29, 2026, scheduled. Low price impact expected for this routine announcement.
4/29/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
First quarter 2026 results scheduled for 2026-04-28; high impact expected as a major financial update.
4/28/2026, 12:00:00 AM